In Vitro Phosphate Binding Capacity of a Dietary Supplement for Dogs and Cats

Natascia  Bruni; Elisa Martello; Raffaella  Adami; Giorgia Meineri; Francesca Perondi; Annalisa Costale; Elena  Rosso; Ilaria Lippi

doi:10.29169/1927-5951.2022.12.08

In Vitro Phosphate Binding Capacity of a Dietary Supplement for Dogs and Cats

Authors

Natascia Bruni Candioli Pharma S.r.l., Beinasco (TO), Italy
Elisa Martello Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, UK
Raffaella Adami Candioli Pharma S.r.l., Beinasco (TO), Italy
Giorgia Meineri Department of Veterinary Sciences, School of Agriculture and Veterinary Medicine, University of Turin, 10095, Grugliasco (TO)
Francesca Perondi Department of Veterinary Science, University of Pisa, 56122 San Piero a Grado (Pisa), Italy
Annalisa Costale Department of Drug Science and Technology, University of Turin, Torino, Italy, Italy
Elena Rosso Department of Drug Science and Technology, University of Turin, Torino, Italy
Ilaria Lippi Department of Veterinary Science, University of Pisa, 56122 San Piero a Grado (Pisa), Italy

DOI:

https://doi.org/10.29169/1927-5951.2022.12.08

Keywords:

Dietary supplement, pet, phosphate binder, renal disorder

Abstract

Hyperphosphatemia has been recognized as a serious and frequent complication in dogs and cats with Chronic Kidney Disease (CKD). The veterinary approach is mainly based on reducing phosphorus in the diet and with phosphate (P) binders. In this in vitro study we compared seven supplements with a different combination of ingredients for dogs and cats at pH 3 and 7 to estimate the P binding capacity overtime. Our results confirmed the best binding capacity of supplements at acid compared to basic condition. The P binding capacity of two products containing mainly calcium carbonate, calcium lactate-gluconate and chitosan was higher compared to the other tested at the same conditions.

References

Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, et al. ISFM Consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg 2016; 18(3): 219-39. https://doi.org/10.1177/1098612X16631234 DOI: https://doi.org/10.1177/1098612X16631234

Bernachon N, Fournel S, Gatto H, Monginoux P, McGahie D. Effect of a product containing the dietary phosphate binders calcium and magnesium carbonate associated with other reno-protectant substances (Pronefra®) on blood parameters and mineral balance in adult cats. Intern J Appl Res Vet Med. 2014; 12.

Martello E, Perondi F, Bruni N, Bisanzio D, Meineri G, Lippi I. Chronic kidney disease and dietary supplementation: effects on inflammation and oxidative stress. Vet Sci 2021; 8(11). https://doi.org/10.3390/vetsci8110277 DOI: https://doi.org/10.3390/vetsci8110277

Biasibetti E, Martello E, Bigliati M, Biasato I, Cocca T, Bruni N, et al. A long term feed supplementation based on phosphate binders in feline chronic kidney disease. Veterinary Research Communications 2018; 42(2): 161-7. https://doi.org/10.1007/s11259-018-9719-z DOI: https://doi.org/10.1007/s11259-018-9719-z

Martello E, Perondi F, Capucchio MT, Biasato I, Biasibetti E, Cocca T, et al. Efficacy of a new dietary supplement in dogs with advanced chronic kidney disease. Peer J 2020; 8: e9663. https://doi.org/10.7717/peerj.9663 DOI: https://doi.org/10.7717/peerj.9663

Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney international Supplement 2004; (90): S25-32. https://doi.org/10.1111/j.1523-1755.2004.09005.x DOI: https://doi.org/10.1111/j.1523-1755.2004.09005.x

Wagner E, Schwendenwein I, Zentek J. Effects of a dietary chitosan and calcium supplement on Ca and P metabolism in cats. Berliner und Munchener tierarztliche Wochenschrift 2004; 117(7-8): 310-5.

Fritz K, Taylor K, Parmar M. Calcium Carbonate. 2022 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing 2022. PMID: 32965974.

Yaguchi A, Akahane K, Tsuchioka K, Yonekubo S, Yamamoto S, Tamai Y, et al. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. BMC Nephrol 2019; 20(1): 465. https://doi.org/10.1186/s12882-019-1655-9 DOI: https://doi.org/10.1186/s12882-019-1655-9

Segev G, Bandt C, Francey T, Cowgill LD. Aluminum toxicity following administration of aluminum-based phosphate binders in 2 dogs with renal failure. J Vet Intern Med 2008; 22(6): 1432-5. https://doi.org/10.1111/j.1939-1676.2008.0206.x DOI: https://doi.org/10.1111/j.1939-1676.2008.0206.x

Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83(1): 66-73. https://doi.org/10.1172/JCI113886 DOI: https://doi.org/10.1172/JCI113886

King EJ. The colorimetric determination of phosphorus. Biochem J 1932; 26(2): 292-7. https://doi.org/10.1042/bj0260292 DOI: https://doi.org/10.1042/bj0260292

Polzin DJ. Chronic kidney disease in small animals. Vet Clin North Am Small Anim Pract 2011; 41(1): 15-30. https://doi.org/10.1016/j.cvsm.2010.09.004 DOI: https://doi.org/10.1016/j.cvsm.2010.09.004

Peitsch T, Matthes M, Brandenburg V, Epple M. An in vitro crystallization setup to assess the efficiency of different phosphate binders in nephrology: quantitative analytical considerations. Analytical Methods 2010; 2(7): 901-11. https://doi.org/10.1039/b9ay00325h DOI: https://doi.org/10.1039/b9ay00325h